Literature DB >> 22546846

Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.

S Otero-Romero1, P Roura, J Solà, J Altimiras, J Sastre-Garriga, C Nos, J Vaqué, X Montalban, E Bufill.   

Abstract

The prevalence of multiple sclerosis in the south of Europe seems to be higher than previously considered. This study aimed to probe a possible increase in the prevalence of multiple sclerosis (MS) in Osona over the past 17 years. This was a cross-sectional study including MS-confirmed cases from several sources of information. Crude and adjusted prevalence rates were obtained. One hundred and twenty patients fulfilled the study criteria. The crude prevalence of MS was 79.9 (95% CI: 66.3-95.6) per 100,000 inhabitants and 91.2 (95% CI: 75.5-109.2) per 100,000 among Spanish born individuals. The prevalence of multiple sclerosis cases in Osona has increased over the past 17 years to being one of the highest reported in Spain.

Entities:  

Mesh:

Year:  2012        PMID: 22546846     DOI: 10.1177/1352458512444751

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.

Authors:  Rainel Sánchez-de la Rosa; Laura García-Bujalance; José Meca-Lallana
Journal:  Health Econ Rev       Date:  2015-10-16

2.  Impact on healthcare resource utilization of multiple sclerosis in Spain.

Authors:  Antoni Sicras-Mainar; Elena Ruíz-Beato; Ruth Navarro-Artieda; Jorge Maurino
Journal:  BMC Health Serv Res       Date:  2017-12-29       Impact factor: 2.655

3.  Is the association between health-related quality of life and fatigue mediated by depression in patients with multiple sclerosis? A Spanish cross-sectional study.

Authors:  Juan J Fernández-Muñoz; Margarita Cigarán-Méndez; Esperanza Navarro-Pardo; Marta Pérez-de-Heredia-Torres; Paula Parás-Bravo; César Fernández-de-Las-Peñas
Journal:  BMJ Open       Date:  2018-01-23       Impact factor: 2.692

4.  Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain.

Authors:  Antoni Sicras-Mainar; Elena Ruíz-Beato; Ruth Navarro-Artieda; Jorge Maurino
Journal:  BMC Neurol       Date:  2017-07-17       Impact factor: 2.474

5.  Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data.

Authors:  Anna Iljicsov; Dániel Milanovich; András Ajtay; Ferenc Oberfrank; Mónika Bálint; Balázs Dobi; Dániel Bereczki; Magdolna Simó
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

6.  Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.

Authors:  Lucía Romero-Pinel; Laura Bau; Elisabet Matas; Isabel León; Roser Juvany; Ramon Jódar; Antonio Martínez-Yélamos; Sergio Martínez-Yélamos
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.240

7.  Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain.

Authors:  Rainel Sanchez-de la Rosa; Eliazar Sabater; Miguel A Casado
Journal:  Health Econ Rev       Date:  2013-05-07

8.  Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.

Authors:  Stéphanie Foulon; Géric Maura; Marie Dalichampt; François Alla; Marc Debouverie; Thibault Moreau; Alain Weill
Journal:  J Neurol       Date:  2017-05-17       Impact factor: 4.849

9.  Risk and outcomes of COVID-19 in patients with multiple sclerosis.

Authors:  Irene Moreno-Torres; Virginia Meca Lallana; Lucienne Costa-Frossard; Celia Oreja-Guevara; Clara Aguirre; Elda María Alba Suárez; Mayra Gómez Moreno; Laura Borrega Canelo; Julia Sabín Muñoz; Yolanda Aladro; Alba Cárcamo; Elena Rodríguez García; Juan Pablo Cuello; Enric Monreal; Susana Sainz de la Maza; Fernando Pérez Parra; Francisco Valenzuela Rojas; Carlos López de Silanes de Miguel; Ignacio Casanova; Maria Luisa Martínez Gines; Rosario Blasco; Aida Orviz García; Luisa María Villar-Guimerans; Guillermo Fernández-Dono; Víctor Elvira; Carmen Santiuste; Mercedes Espiño; José Manuel García Domínguez
Journal:  Eur J Neurol       Date:  2021-07-18       Impact factor: 6.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.